Arcutis Biotherapeutics, Inc. (ARQT)

USD 13.4

(-9.83%)

Market Cap (In USD)

1.56 Billion

Revenue (In USD)

59.6 Million

Net Income (In USD)

-262.14 Million

Avg. Volume

2.33 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.51-15.02
PE
-
EPS
-
Beta Value
1.185
ISIN
US03969K1088
CUSIP
03969K108
CIK
1787306
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Todd Franklin Watanabe M.A.
Employee Count
-
Website
https://www.arcutis.com
Ipo Date
2020-01-31
Details
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.